Two new therapies offer hope for pancreatic cancer, showing encouraging results in clinical studies

Researchers are reporting significant advances in oncology, particularly for pancreatic cancer, with the emergence of new immunotherapies. George Pavlakis, a researcher and visiting professor at Emory University in Atlanta, presented these developments, emphasizing that while not definitive cures, they offer substantial hope.

One innovation is a targeted pill therapy that acts on a specific gene linked to tumor growth. Unlike chemotherapy, this approach blocks mechanisms responsible for cancer cell multiplication. Clinical studies suggest this treatment could double the survival time for pancreatic cancer patients, a group facing one of the most aggressive and difficult-to-treat cancers. However, the treatment is not a complete cure, as tumors can develop resistance.

Experts anticipate that combining therapies will yield the greatest benefits, potentially transforming cancer into a manageable chronic condition. A second development involves an experimental injectable therapy using monoclonal antibodies, currently in trials, which has shown particularly encouraging results. This therapy targets different mechanisms on cancer cell surfaces, appearing to destroy them more effectively.

While the injectable therapy requires further study before approval, scientists consider it highly promising for various tumor types. The targeted pill is expected to receive approval in the US and Europe soon, whereas the antibody therapy remains in the research phase. Both advancements signal a shift toward more targeted and personalized treatments that aim to gradually alter cancer care.

“

steps forward that, although not a definitive solution, create well-founded hopes.